Jemincare
Quick facts
Marketed products
- Sonidegib Phosphate Capsules · Oncology
Sonidegib is a Hedgehog pathway inhibitor that blocks Smoothened (SMO) signaling to suppress aberrant cell proliferation driven by Hedgehog pathway activation.
Phase 3 pipeline
- JMKX001899 · Immunology
JMKX001899 is a small molecule that targets the S1P1 receptor. - JYB1904 · Autoimmune diseases
JYB1904 is a small molecule targeting the S1P1 receptor. - Placebo+JYB1904
JYB1904 is an investigational therapeutic being evaluated in combination with placebo control in a Phase 3 trial, though its specific molecular mechanism is not publicly disclosed.
Phase 2 pipeline
- JMKX000189
- JMKX000623
- JMKX003002 will be administered orally
- JMKX003142 Injection
- JMKX003142 tablets
- JMKX003142 will be administered orally
- Torasemide tablets
Phase 1 pipeline
- [14C]JMKX003142
- [14C]JMKX003142 solution for infusion
- Amiodarone Hydrochloride Tablets
- Cohort 1: JMKX003142 and itraconazole
- Cohort 2: JMKX003142 and rifampicin
- JMKX000197
- JMKX003801
- JMKX003948
- JMKX003948 Ophthalmic Suspension
- JMKX005425
- JYB1907
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: